Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk ...

Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.

Alecensa (alectinib) is now an option for patients with stage 1b to 3a ALK-positive NSCLC who have ... In another positive development for the lung cancer community, NICE has also given its ...

AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) for the use of its lung cancer treatments, Tagrisso (osimertinib) and ...

Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even before symptoms occur.

Tagrisso has been recommended for use as an adjuvant treatment following complete resection in adults with stage 1B to 3A non-small cell lung cancer (NSCLC) whose tumours express epidermal growth ...